Announcements Trials
Browse Landscape

Phase

Phase 4 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Pain 1Neoplasms 1Cancer Pain 1Breakthrough Pain 1

Interventions

Cyclophosphamide 3155Cisplatin 3151Carboplatin 2929Paclitaxel 2671Radiotherapy 2643Gemcitabine 2544pembrolizumab 2324Docetaxel 2154Bevacizumab 2126Fluorouracil 1819Capecitabine 1780Oxaliplatin 1709Dexamethasone 1589Nivolumab 1516Doxorubicin 1477Rituximab 1453Etoposide 1341Magnetic Resonance Spectroscopy 1261Irinotecan 1232Leucovorin 1212Cytarabine 1123Pemetrexed 1060Drug Therapy 1060fludarabine 1044Vincristine 956Specimen Handling 928Prednisone 924Cetuximab 919Lenalidomide 916Trastuzumab 897

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Ultracet × Clear all
NCT01968018 2013-10-23

A Study of Safety and Effectiveness of Ultracet in Patients With Chronic Cancer Pain

Janssen-Cilag Ltd.,Thailand

Phase 4 Completed
35 enrolled
Tumor-Agnostic

Neoplasms

NCT00576173 2010-04-28

An Open Label Study to Evaluate Safety, Tolerability and Clinical Utility of ULTRACET® (37.5mg Tramadol Hydrochloride/325mg Acetaminophen) for the Treatment of Breakthrough Pain in Cancer Patients

Johnson & Johnson Taiwan Ltd

Phase 4 Completed
60 enrolled

Cancer Pain, Pain, Breakthrough Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡